These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 9271164)
41. [Protective action of a vaccine made from Salmonella minnesota R 595 in the intranasal infection of mice with P. aeruginosa]. Apollonin AV Zh Mikrobiol Epidemiol Immunobiol; 1983 Jul; (7):73-7. PubMed ID: 6624314 [TBL] [Abstract][Full Text] [Related]
42. Serological relationships between Escherichia coli and Salmonella smooth- and rough-mutant lipopolysaccharides as revealed by enzyme-linked immunosorbent assay for human immunoglobulin G antiendotoxin antibodies. Barclay GR; Scott BB Infect Immun; 1987 Nov; 55(11):2706-14. PubMed ID: 3312008 [TBL] [Abstract][Full Text] [Related]
43. Qualitative analysis of antibody binding. An in vitro assay for the evaluation and development of vaccines. Bruderer U; Fürer E; Cryz SJ; Lang AB J Immunol Methods; 1990 Oct; 133(2):263-8. PubMed ID: 2121830 [TBL] [Abstract][Full Text] [Related]
44. Experimental chronic Pseudomonas aeruginosa lung infection in rats. Non-specific stimulation with LPS reduces lethality as efficiently as specific immunization. Lange KH; Hougen HP; Høiby N; Fomsgaard A; Rygaard J; Johansen HK APMIS; 1995 May; 103(5):367-74. PubMed ID: 7654361 [TBL] [Abstract][Full Text] [Related]
45. [Protective role of Salmonella R mutants in Salmonella infection in mice (author's transl)]. Schlecht S; Westphal O Zentralbl Bakteriol Orig A; 1979 Oct; 245(1-2):71-88. PubMed ID: 44625 [TBL] [Abstract][Full Text] [Related]
46. Specific and non-specific mouse protection induced by different chemotypes of the Pseudomonas aeruginosa lipopolysaccharides. Stanislavsky ES; Makarenko TA; Kozhenova TE FEMS Microbiol Immunol; 1992 Oct; 5(4):181-9. PubMed ID: 1419116 [TBL] [Abstract][Full Text] [Related]
47. [Immunosuppressive effects of pathogenic gram-negative bacteria]. Vorob'ev AA; Borisova EV; Molozhavaia OS; Borisov VA Vestn Ross Akad Med Nauk; 2001; (2):21-5. PubMed ID: 11338500 [TBL] [Abstract][Full Text] [Related]
48. Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni. O'Ryan M; Vidal R; del Canto F; Carlos Salazar J; Montero D Hum Vaccin Immunother; 2015; 11(3):601-19. PubMed ID: 25715096 [TBL] [Abstract][Full Text] [Related]
49. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5. Baumgartner JD; Heumann D; Calandra T; Glauser MP J Infect Dis; 1991 Apr; 163(4):769-72. PubMed ID: 2010630 [TBL] [Abstract][Full Text] [Related]
50. Development of an enzyme-linked immunosorbent assay for studying Pseudomonas aeruginosa cell surface antigens. Borowski RS; Stock LM; Schiller NL J Clin Microbiol; 1984 Jun; 19(6):736-41. PubMed ID: 6206085 [TBL] [Abstract][Full Text] [Related]
51. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia. Pennington JE; Pier GB; Sadoff JC; Small GJ Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209 [TBL] [Abstract][Full Text] [Related]
52. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Finke M; Duchêne M; Eckhardt A; Domdey H; von Specht BU Infect Immun; 1990 Jul; 58(7):2241-4. PubMed ID: 2114360 [TBL] [Abstract][Full Text] [Related]
55. An enzyme-linked immunosorbent assay (ELISA) for the measurement of antibodies to different parts of the gram-negative lipopolysaccharide core region. Appelmelk BJ; Verweij-Van Vught AM; MacLaren DM; Thijs LG J Immunol Methods; 1985 Oct; 82(2):199-207. PubMed ID: 2413127 [TBL] [Abstract][Full Text] [Related]
56. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420 [TBL] [Abstract][Full Text] [Related]
57. Membrane vesicles derived from Pseudomonas aeruginosa and Shigella flexneri can be integrated into the surfaces of other gram-negative bacteria. Kadurugamuwa JL; Beveridge TJ Microbiology (Reading); 1999 Aug; 145 ( Pt 8)():2051-2060. PubMed ID: 10463171 [TBL] [Abstract][Full Text] [Related]
58. [Experimentally determined safety and immunological activity of vaccine based on antigens isolated from Pseudomonas aeruginosa in medium K-4]. Nuriddinova NR; Sheremet'ev NN; Ivanova LE; Garib FIu; Iskhakova KhI Zh Mikrobiol Epidemiol Immunobiol; 2005; (3):57-60. PubMed ID: 16028515 [TBL] [Abstract][Full Text] [Related]
59. [Experimental study of the protective activity of vaccines made from 7 Pseudomonas aeruginosa immunotypes]. Kholodkova EV; Fedotova IuM; Stanislavskiĭ ES Zh Mikrobiol Epidemiol Immunobiol; 1987 Aug; (8):47-50. PubMed ID: 2446445 [TBL] [Abstract][Full Text] [Related]